ReviewHandbook of experimental pharmacology2026
Hydrogen Sulfide in Experimental Organ Transplantation: From Bench to Bedside.
Review in Handbook of experimental pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organ transplantation is the treatment of choice for patients with organ failure. However, the long-term success of this complex life-saving procedure is severely challenged by several inherent factors such as ischemia-reperfusion injury (IRI), an unavoidable pathological condition which occurs due to temporary cessation of blood supply to the donor organ during procurement and cold preservation, and subsequent blood restoration upon engraftment. IRI decreases organ graft quality and function and increases the incidence of post-transplant complications. While the transplant community has adopted the use of sub-optimal organ grafts from extended criteria donors and deceased donors in addition to viable organs from healthy living donors to expand the pool of transplantable organs with the aim to overcome the global organ shortage crisis, the sub-optimal organs are more susceptible to IRI. Also worrying is the fact that organ preservation techniques have not changed for over the last 50 years, suggesting the need to optimize existing preservation techniques or develop effective alternative preservation solutions to limit ischemic injury during organ graft preservation. Among several pharmacological agents being tested in preservation solutions in the pretext of improving transplantation outcomes, hydrogen sulfide (H
Indexed as
Identifiers
41436658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.